Squamous cell carcinoma of the lower lip involving a large cutaneous surface. Photodynamic therapy as an alternative therapy

Gross, D. J.

doi:10.1001/archderm.126.9.1148

Cited by 10 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past 10 years, PDT with systemic Photofrin® has been used for multiple types of cutaneous and subcutaneous malignancies including basal cell carcinoma [7,45], widespread Bowen's disease [45--47], squamous cell carcinoma [48][49][50][51][52], metastatic and recurrent breast carcinoma [50,51,[53][54][55] and Kaposi's sarcoma [56]. In a few instances PDT has also been used for palliation of metastatic melanoma [ 50,51,54 ].…”

Section: Introduction and Early Clinical Resultsmentioning

confidence: 99%

Photodynamic therapy: a promising new modality for the treatment of cancer

Schuitmaker

Baas

Leengoed

et al. 1996

Journal of Photochemistry and Photobiology B: Biology

273

128

View full text Add to dashboard Cite

The first reports on photodynamic therapy (PDT) date back to the 1970s. Since then, several thousands of patients, both with early stage and advanced stage solid tumours, have been treated with PDT and many claims have been made regarding its efficacy. Nevertheless, the therapy has not yet found general acceptance by oncologists. Therefore it seems legitimate to ask whether PDT can still be described as "'a promising new therapy in the treatment of cancer".Clinically, PDT has been mainly used for bladder cancer, lung cancer and in malignant diseases of the skin and upper aerodigestive tract. The sensitizer used in the photodynamic treatment of most patients is Photofrin®, (Photofrin®, the commercial name of dihematoporphyrin ether/ester, containing > 80% of the active porphyrin dimers/oligomers (A.M.R. Fisher, A.L. Murphee and C.J. Gomer, Clinical and preclinical photodynamictherapy, Review Series Article, Lasers Surg. Med., 17 (1995) 2-31 ). It is a complex mixture of porphyrins derived from hematoporphyrin. Although this sensitizer is effective, it is not the most suitable photosensitizer for PDT. Prolonged skin photosensitivity and the relatively low absorbance at 630 rim, a wavelength where tissue penetration of light is not optimal, have been frequently cited as negative aspects hindering general acceptance. A multitude of new sensitizers is currently under evaluation. Most of these "second generation photosensitizers" are chemically pure, absorb light at around 650 nm or greater and induce no or less general skin photosensitivity. Another novel approach is the photosensitization of neoplasms by the induction of endogenous photosensitizers through the application of 5-aminolevulinic acid (ALA). This article addresses the use of PDT in the disciplines mentioned above and attempts to indicate developments of PDT which could be necessary for this therapy to gain a wider acceptance in the various fields.

show abstract

Section: Introduction and Early Clinical Resultsmentioning

confidence: 99%

Photodynamic therapy: a promising new modality for the treatment of cancer

Schuitmaker

Baas

Leengoed

et al. 1996

Journal of Photochemistry and Photobiology B: Biology

273

128

View full text Add to dashboard Cite

show abstract

Hyperthermia potentiates the effects of aluminum phthalocyanine tetrasulfonate‐mediated photodynamic toxicity in human malignant and normal cell lines

et al. 1991

View full text Add to dashboard Cite

The purpose of this study was to examine the effects of photodynamic therapy utilizing aluminum phthalocyanine tetrasulfonate in vitro on several human malignant and normal cell types, with or without hyperthermia. Cells examined included normal skin fibroblasts, HT-1080 fibrosarcoma cells, SCC-25 (squamous cell carcinoma) and malignant melanoma cells. An argon-pumped continuous wave tunable dye laser at 675 nm was used as the light source, hyperthermia groups were heated to 42.5 degrees C, and radioisotope incorporation was used to measure DNA and protein synthesis as toxicity assays. Results showed an energy-dose, and A1PcS-concentration dependent toxicity in all cell lines examined, with moderate selectivity toward malignant cells. Hyperthermia alone was slightly toxic in melanomas and HT-1080 cell lines but had no effect in normal fibroblasts or SCC-25 cells. Hyperthermia synergistically potentiated the effects of PDT in all cell lines, and the combined modality was significantly more toxic in all malignant cell lines compared with normal cells. Thus, addition of hyperthermia to PDT protocols may enhance the efficacy of this treatment modality in vitro.

show abstract